ZNF659 Inhibitors
ZNF659 inhibitors encompass a diverse range of chemical compounds that indirectly attenuate the functional activity of ZNF659 through various signaling pathways. Cyclosporin A and Rapamycin, for instance, target the calcineurin/NFAT and mTOR pathways, respectively, which are crucial for T-cell activation, apoptosis, and DNA damage response-a domain where ZNF659 is active. These inhibitors effectively hinder pathways that regulate ZNF659, leading to a reduction in its functional capacity in immune response and genomic stability maintenance. Similarly, PI3K inhibitors like LY 294002 and Wortmannin disrupt the PI3K/AKT/mTOR axis, which is intimately connected to cell survival and DNA repair mechanisms, thereby potentially decreasing ZNF659's involvement in these essential cellular processes.
The chemical landscape that potentially moderates ZNF659 activity extends to other signaling molecules and pathways implicated in cellular stress responses and survival. Bortezomib, by inhibiting proteasome activity, stabilizes IκB and thereby suppresses NF-κB-mediated transcription, which could downregulate genes under the regulatory umbrella of ZNF659. SB 203580's inhibition of p38 MAPK similarly disrupts stress response signaling, further contributing to a decrease in ZNF659's functional influence in such pathways. Moreover, the modulation of the Wnt/β-catenin pathway by Sulindac and the attenuation of tyrosine kinase activity by Imatinib both serve to reduce the transcriptional and growth-promoting activities that ZNF659 could facilitate. Lastly, Etoposide's induction of DNA strand breaks by inhibiting topoisomerase II, paradoxically, could saturate the DNA repair system, potentially overwhelming ZNF659's capacity to contribute to genomic integrity. Collectively, these inhibitors function through distinct but interconnected biochemical pathways to indirectly limit the functional activity of ZNF659, each contributing to a concerted diminution of its role in cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits the phosphatase activity of calcineurin. This inhibition impedes the NFAT (nuclear factor of activated T-cells) pathway, which may downregulate ZNF659 as it is involved in T-cell activation and apoptosis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR, which is part of the PI3K/AKT/mTOR pathway. As ZNF659 plays a role in DNA damage responses, mTOR inhibition can diminish ZNF659's activity in this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that decreases AKT phosphorylation, thereby reducing the activity of downstream proteins involved in cell survival and DNA repair; this action can indirectly diminish ZNF659's activity in these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which can lead to decreased AKT activity and subsequent downregulation of survival pathways, potentially leading to a diminished functional state of ZNF659 in DNA damage response. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin is known to inhibit NF-κB signaling, which can decrease the expression of genes involved in inflammation and survival, including those potentially regulating ZNF659. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor, which by inhibiting the MAPK/ERK pathway, could lead to reduced activity of downstream DNA repair proteins, potentially diminishing the functional role of ZNF659 in these processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which could inhibit the JNK signaling pathway, potentially reducing the activity of proteins involved in apoptosis and DNA repair where ZNF659 might be implicated. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, potentially reducing the activity of proteins in the stress response pathway, which could indirectly decrease ZNF659's function in the cellular response to DNA damage. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor; by preventing the degradation of IκB, it inhibits NF-κB. Since NF-κB signaling can regulate genes involved in survival, this could diminish ZNF659's role in these pathways. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $32.00 $86.00 $150.00 | 3 | |
Sulindac can inhibit the Wnt/β-catenin pathway, which could lead to reduced transcriptional activity of genes involved in cell proliferation where ZNF659 might have a role. | ||||||